December 17, 2015
ORIG3N™ Closes $12.5 Million in Funding Lead by Hatteras Venture Partners and Syno Capital
BOSTON, Dec. 16, 2015 /PRNewswire/ — ORIG3N Inc., a biotechnology company developing breakthrough treatments for rare and genetically inherited diseases and a pioneer in regenerative medicine announces the close of a $12.5 million Series A financing from an investor syndicate co-led by Hatteras Venture Partners and Syno Capital.
December 17, 2015
Clearside Biomedical, Inc. Completes $20 Million Series C Financing
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the closing of a $20 million Series C financing.
December 4, 2015
5 Mission-Driven Companies That Are Changing The World
When I was a senior in college, my career goals were fairly simple. I wanted to work for a company that was doing something I cared deeply about. So, when I started actually looking for jobs, I limited my search to non-profits, because, well, in my mind: non-profits = world changers, for-profits = EVIL EMPIRES OF EVIL.
October 29, 2015
Startup Qvella gets $20M Series A to develop rapid pathogen detection test
It’s been more than a decade in the making, but Qvella is close to the holy grail of diagnostics–a compact, inexpensive pathogen analyzer that identifies the precise culprit in only 30 minutes. The idea is to enable better infection treatment faster as well as to minimize the overuse of antibiotics, which leads to the development of resistance.
September 1, 2015
Patient engagement platform Medfusion reels in $3 million
CARY, N.C., Sept. 1, 2015 /PRNewswire/ — Medfusion, Inc., a patient engagement platform dedicated to facilitating the relationship between doctors and patients, today announced a $3 million investment from two Durham, N.C.-based venture capital firms.
August 25, 2015
Hatteras Venture Partners Announces First Closing of HVP V
August 24, 2015 – Durham, NC – Hatteras Venture Partners announced today the first closing of Hatteras Venture Partners V (HVP V) with more than $90 million in subscriptions towards a final fund target of $150 million. In addition, Hatteras has entered a partnership with Malin Corporation PLC to bolster the firm’s strategic partnering capacity to grow portfolio companies from the seed stage to maturity.
August 11, 2015
G1 Therapeutics Announces Initiation of Two Phase 1b/2a Trials of CDK4/6 Inhibitor G1T28 in Small-Cell Lung Cancer
RESEARCH TRIANGLE PARK, NC, August 11, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that it has initiated two Phase 1b/2a trials of the CDK4/6 inhibitor G1T28 in patients with small-cell lung cancer (SCLC). G1T28 is an intravenous (IV) therapy being studied as a bone marrow and immune system chemoprotectant in patients with SCLC who are receiving chemotherapy.
August 6, 2015
Aerie Pharmaceuticals and GrayBug Announce Research Collaboration Focused on Novel Delivery Technologies for Aerie Product Candidates
IRVINE, California & BALTIMORE, Maryland – (BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced a research collaboration and license agreement to deliver certain of Aerie’s preclinical product candidates to both the front and back of the eye using GrayBug’s proprietary technology.
June 30, 2015
Wildflower Health secures $5 million in financing to expand mobile, enterprise platform for maternity and family health
SAN FRANCISCO, June 25, 2015 — Wildflower Health, maker of mobile maternity program Due Date Plus (www.wildflowerhealth.com/programs), today announced a $5 million investment in the company to facilitate its strategic expansion. New investors Easton Capital and Hatteras Venture Partners led the funding round with participation by existing investors Cambia Health Solutions and HealthTechCapital.
May 19, 2015
ORIG3N™ Announces Strategic Collaboration with LabCorp
BOSTON, May 19, 2015 /PRNewswire/ — ORIG3N, Inc., a pioneer in regenerative medicine and provider of induced pluripotent stem cell (iPSC) storage, called LifeCapsule (www.capsule.life), today announced a strategic collaboration order tramadol online c.o.d with Laboratory Corporation of America® Holdings (LabCorp®) (LH).